Metastatic Solid Tumor Clinical Trials in Houston, Texas

18 studies are recruiting for metastatic solid tumor in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

   This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   18 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT05898399 on ClinicalTrials.gov

3. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT MD Anderson, Houston, Texas

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

4. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

   The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06561685 on ClinicalTrials.gov

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

6. A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

   The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours. Advanced solid tumours are cancers that can occur in various organs or tissues and have spread from their original site to nearby tissues or oth…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   10 in total

   Run by

   Ipsen

   See if you can join NCT07213830 on ClinicalTrials.gov

7. A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

   This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phase…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   12 in total

   Run by

   Ipsen

   See if you can join NCT07213817 on ClinicalTrials.gov

8. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

   This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   36 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05875168 on ClinicalTrials.gov

9. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

   This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigative Site #129, Houston, Texas

   Locations

   15 in total

   Run by

   MOMA Therapeutics

   See if you can join NCT06974110 on ClinicalTrials.gov

10. A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

    To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05673928 on ClinicalTrials.gov

11. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #9, Houston, Texas

    Locations

    11 in total

    Run by

    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

12. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evalu…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    74 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT05384626 on ClinicalTrials.gov

13. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    26 in total

    Run by

    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

14. A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

    Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-sm…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT06521554 on ClinicalTrials.gov

15. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

16. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

    This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    10 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06108050 on ClinicalTrials.gov

17. A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

    Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid …

    Stage

    Phase 1

    Ages

    12 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    63 in total

    Run by

    Nuvalent Inc.

    See if you can join NCT05118789 on ClinicalTrials.gov

18. A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer

    This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given ev…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    7 in total

    Run by

    SOTIO Biotech AG

    See if you can join NCT06163391 on ClinicalTrials.gov